Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
5 April 2018 07.00 BST
NON-EXECUTIVE DIRECTORS' RETIREMENT PLANS
AstraZeneca
PLC (the Company) announced today that Rudy Markham and Shriti
Vadera will be proposed to shareholders for re-election as
Directors for the final time at the Company's AGM on 18 May
2018.
Mr
Markham intends to retire from the Board at the conclusion of the
2019 AGM. Although he has served as a Director for over nine years,
the Board continues to consider him to be independent in character
and judgement, as evidenced by the way in which he discharges his
duties as a Board and Board Committee member. The Board also
believes it would be in the best interests of shareholders for him
to serve for one further year, during a period of Board changes,
given his depth of knowledge of the Company and significant
non-executive experience. Subject to his re-election by
shareholders, his continued tenure will provide a degree of
continuity following the appointment of several new Non-Executive
Directors to succeed retiring Board members in 2017 and 2018, and
will also facilitate an orderly transition of the roles of Chairman
of the Audit Committee and senior independent
Director.
Baroness
Vadera has informed the Board that she will retire as a Director by
31 December 2018, by when she will have served as a Board member
for eight years.
The
Company will announce related Board Committee changes and Mr
Markham's successor as senior independent Director as soon as
possible following these being decided.
The
Company's Annual Report and Form 20-F Information 2017 was
published on 6 March 2018.
The
Notice of Annual General Meeting 2018 and Shareholders' Circular
will be published in mid-April 2018.
The
meeting place for the Annual General Meeting will be the Royal
Lancaster London Hotel, Lancaster Terrace, London W2 2TY and the
meeting will commence at 2.30 pm (BST) on 18 May 2018.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. The Company also is selectively active
in the areas of autoimmunity, neuroscience and infection.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients
worldwide.
For more information, please visit www.astrazeneca.com
and follow us on Twitter
@AstraZeneca.
|
Media
Relations
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
|
|
Investor
Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
|
Craig
Marks
|
Finance;
Fixed Income; M&A
|
+44
7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
|
Mitchell
Chan
|
Oncology;
Other
|
+1 240
477 3771
|
|
Christer
Gruvris
|
Brilinta; Diabetes
|
+44 203
749 5711
|
|
Nick
Stone
|
Respiratory;
Renal
|
+44 203
749 5716
|
|
US toll
free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
05 April
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|